Cerebrospinal fluid epinephrine in Alzheimer's disease and normal aging

Neuropsychopharmacology

Volumn 19, Issue 6, 1998, Pages 465-471

  Peskind, Elaine R ^b,c,d   Elrod, Rachael ^d   Dobie, Dorcas J ^b,c,d   Pascualy, Marcella ^a,c,d   Petrie, Eric ^c,d   Jensen, Carl ^c,d   Brodkin, Kayla ^a   Murray, Sharon ^b,c   Veith, Richard C ^a,c,d   Raskind, Murray A ^b,c,d  

^a VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^b Education   (United States)

^c Mental Health Service   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Adrenergic; Aging; Alzheimer's disease; Cerebrospinal fluid; Clonidine; Epinephrine; Yohimbine

Indexed keywords

ADRENALIN; CLONIDINE; YOHIMBINE;

ADRENERGIC ACTIVITY; ADULT; AGED; AGING; AGITATION; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

ADRENERGIC ALPHA-AGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ADULT; AGED; AGING; ALZHEIMER DISEASE; BLOOD PRESSURE; CLONIDINE; EPINEPHRINE; FEMALE; HEART RATE; HUMANS; MALE; YOHIMBINE;

EID: 0031751746     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(98)00054-2     Document Type: Article

References (32)

1. Acheson A.L., Zigmond M.J. Short- and long-term changes in tyrosine hydroxylase activity in rat brain after substantial destruction of central noradrenergic neurons. J Neurosci. 1:1981;493-504.
2. Acheson A.L., Zigmond M.J., Stricker E.M. Compensatory increase in tyrosine hydroxylase activity in rat brain after intraventricular injections of 6-hydroxydopamine. Science. 207:1980;537-540.
3. Burke W.J., Chung H.D., Marshall G.L., Gillespie K.N., Joh T.H. Evidence for decreased transport of PNMT protein in advanced Alzheimer's disease. JAGS. 38:1990;1275-1282.
4. Burke W.J., Galvin N.J., Chung H.D., Stoff S.A., Gillespie K.N., Cataldo A.M., Nixon R.A. Degenerative changes in epinephrine tonic vasomotor neurons in Alzheimer's disease. Brain Res. 661:1994;35-42.
5. Elrod R., Peskind E.R., DiGiacomo L., Brodkin K.I., Veith R.C., Raskind M.A. Effects of Alzheimer's disease severity on cerebrospinal fluid norepinephrine concentration. Am J Psychiat. 154:1997;25-30.
6. Esler M.D., Kaye D.M., Thompson J., Jennings G., Cox H., Turner A.G., Lambert G., Seals D. Effects of aging on epinephrine secretion and regional release of epinephrine from the human heart. J Clin Endocrinol Metab. 80:1995;435-442. a.
7. Esler M.D., Turner A.G., Kaye D.M., Thompson J.M., Kingwell B.A., Morris M., Lambert G.M., Jennings G.L., Cox H.S., Seals D.R. Effects of aging on human sympathetic neuronal function. Am J Physiol. 268:1995;R278-R285. b.
8. Evans M.I., Halter J.B., Porte D. Jr. Comparison of double- and single-isotope enzymatic derivative methods for measuring catecholamines in human plasma. Clin Chem. 24:1978;567.
9. Folstein M.F., Folstein S.E., McHugh P.R. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician J Psychiat Res. 12:1975;189-198.
10. Fuller R.W. Pharmacology of brain epinephrine neurons. Ann Rev Pharmacol Toxicol. 22:1982;31-55.
11. Gianutsos G., Moore K.E. Epinephrine contents of sympathetic ganglia and brain regions of spontaneously hypertensive rats of different ages. Pro Soc Exp Biol Med. 158:1978;45-49.
12. Introini-Collison I., Saghafi D., Novack G.D., McGaugh J.L. Memory-enhancing effects of post-training dipivefrin and epinephrine. Involvement of peripheral and central adrenergic receptors Brain Res. 572:1992;81-86.
13. Kalia M., Fuxe K., Goldstein M. Rat medulla oblongata. III. Adrenergic (C1 and C2) neurons, nerve fibers and presumptive terminal processes. J Comp Neurol. 233:1985;333-349.
14. Le Corre P.A., Peskind E.R., Chevanne F., Raskind M.A., Le Verge R. Cerebrospinal fluid and plasma disposition of yohimbine and 11-hydrox-yohimbine in young and older healthy subjects and Alzheimer's disease patients. Eur J Clin Pharmacol. 52:1997;135-138.
15. Lewis S.J., Rowe P., Jarrott B. Involvement of hypothalamic adrenaline in the clonidine withdrawal syndrome in normotensive and spontaneously hypertensive rats. Clin Expl Pharmacol Physiol. 15:1988;773-780.
16. Li Y.W., Bayliss D.A., Guyenet P.G. C1 neurons of neonatal rats. Intrinsic beating properties and α2-adrenergic receptors Am J Physiol. 269:1995;R1356-R1369.
17. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadian E.M. Clinical diagnosis of Alzheimer's disease. Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease Neurology. 34:1984;939-944.
18. Morrow L.A., Linares O.A., Hill T.J., Sanfield J.A., Supiano M.A., Rosen S.G., Halter J.B. Age differences in the plasma clearance mechanism for epinephrine and norepinephrine in humans. J Clin Endo Metab. 65:1987;508-511.
19. Murburg M.M., Villacres E.C., Ko G.N., Veith R.C. Effects of yohimbine on human sympathetic nervous system function. J Clin Endo Metab. 73:1991;861-865.
20. Nakamura S., Sakaguchi T. Development and plasticity of the locus coeruleus. A review of recent physiological and pharmacologic experimentation Prog Neurobiol. 34:1990;505-526.
21. Overall J.E., Beller S.A. The Brief Psychiatric Rating Scale (BPRS) in geropsychiatric research I. Factor structure on an inpatient unit J Gerontol. 39:1983;187-193.
22. Overall J.E., Gorham D.R. The Brief Psychiatric Rating Scale. Psychol Rep. 10:1962;799-812.
23. Peskind E.R., Wingerson D., Murray S., Pascualy M., Dobie D.J., Le Corre P., Le Verge R., Veith R.C., Raskind M.A. Effects of Alzheimer's disease and normal aging on cerebrospinal fluid norepinephrine responses to yohimbine and clonidine. Arch Gen Psychiat. 52:1995;774-782.
24. Reisberg B., Borenstein J., Salob S.P., Ferris S.H., Franssen E., Georgotas A. Behavioral symptoms in Alzheimer's disease. Phenomenology and treatment J Clin Psychiat. 48:1987;9-15.
25. Russo-Neustadt A., Cotman C.W. Adrenergic receptors in Alzheimer's disease brain. Selective increases in the cerebella of aggressive patients J Neurosci. 17:1997;5573-5580.
26. Schmidt M.E., Matuchik J.A., Goldstein D.S., Schouten J.L., Zametkin J.A., Potter W.Z. Gender differences in brain metabolic and plasma catecholamine responses to alpha-adrenoreceptor blockade. Neuropsychopharmacology. 16:1997;298-310.
27. Shankle W.R., Nielson K.A., Cotman C.W. Low-dose propranolol reduces aggression and agitation resembling that associated with orbitofrontal dysfunction in elderly demented patients. Alz Dis Assoc Dis. 9:1995;233-237.
28. Vitiello B., Veith R.C., Molchan S.E., Martinez R.A., Lawlor B.A., Radcliffe J., Hill J.L., Sunderland T. Autonomic dysfunction in patients with dementia of the Alzheimer's type. Biol Psychiat. 34:1993;428-433.
29. Weil-Malherbe H., Axelrod J., Tomchick R. Blood-brain barrier for adrenaline. Science. 129:1959;1226-1227.
30. Weiler P.G., Mungas D., Bernick C. Propranolol for the control of disruptive behavior in senile dementia. J Geriatr Psychiat Neurol. 1:1988;226-230.
31. Wilkie F.L., Halter J.B., Prinz P.N., Benedetti C., Eisdorfer C., Atwood B., Yamasaki D. Age-related changes in venous catecholamines basally and during epinephrine infusion in man. J Gerontol. 40:1985;133-140.
32. Yudofsky S., Williams D., Gorman J. Propranolol in the treatment of rage and violent behavior in patients with chronic brain syndromes. Am J Psychiat. 138:1981;218-220.